Kathryn Michele Jurenovich, DO Orthopaedic Surgery - Orthopaedic Surgery of the Spine Medicare: Medicare Enrolled Practice Location: 7630 Southern Blvd, Boardman, OH 44512 Phone: 330-729-8000 |
Sheryl R Handler-matasar, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 6505 Market St Bldg A, Boardman, OH 44512 Phone: 330-746-8070 Fax: 330-729-1946 |
Jack Dawson, DO Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8423 Market St Ste 207, Boardman, OH 44512 Phone: 330-965-5490 Fax: 330-965-5491 |
Dr. Jeffrey Thomas Johnston, M.D. Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 835 Mckay Ct Ste 100, Boardman, OH 44512 Phone: 330-758-4399 Fax: 330-748-8995 |
Dr. Douglas H Musser, D.O. Orthopaedic Surgery - Orthopaedic Surgery of the Spine Medicare: Accepting Medicare Assignments Practice Location: 1499 Boardman Canfield Rd, Boardman, OH 44512 Phone: 330-758-0577 Fax: 330-533-4587 |
News Archive
In South Florida, when people want to find a Black physician, they often contact Adrienne Hibbert through her website, Black Doctors of South Florida.
Patients treated for their prolonged seizures with the sedative propofol may be at high risk for complications and even death. New research presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that the use of propofol as an antiepileptic agent in patients with refractory status epilepticus (RSE), prolonged seizures that do not respond to initial treatment, was associated with significant mortality and morbidity.
In their new paper available on the bioRxiv* preprint server, US researchers from the OpenBiome nonprofit organization used a mathematical model to simulate the usefulness of different testing strategies for fecal samples and showed that the probability of releasing a fecal microbiota donation with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is low when several important variables are taken into account.
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.
› Verified 1 days ago